Monday , October 23 2017
Home / Therapies / SGLT-2 Therapy Center / Christophe Arbet-Engels, MD, Q6: SGLT-2 Safety Profile

Christophe Arbet-Engels, MD, Q6: SGLT-2 Safety Profile

Dr. Christophe Arbet-Engels talks about the empagliflozin studies and the ongoing safety program to identify any safety and side-effect concerns. However, despite reported potential urinary tract and genital infection issues, the large majority of patients of the study’s 14,000 participants didn’t observe any of these effects.

Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

See more SGLT-2 Resources